Targeting JAK kinase in solid tumors: emerging opportunities and challenges.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Human malignancies often exhibit overactive Janus kinases (JAK) and STAT3/STAT5 signaling.
• This activation is frequently driven by inflammatory cytokines in the tumor microenvironment, produced by immune cells.
• Cytokines like IL-6, IL-10, and IL-23 families play a significant role in this process.

Purpose of the Study:

• To review preclinical applications of JAK inhibitors for solid cancers.
• To focus on gastric and colon cancers, common malignancies of epithelial mucosa.
• To explore the therapeutic potential of JAK/STAT3 pathway interference in drug-resistant and sporadic cancers.

Main Methods:

• Review of preclinical studies involving JAK inhibitors in mouse models of solid cancers.
• Analysis of genetic findings related to JAK/STAT3 pathway activation.
• Examination of emerging data on small molecule JAK-specific inhibitors.

Main Results:

• JAK/STAT3 pathway inhibition demonstrates potential to suppress cancer hallmarks like proliferation and angiogenesis.
• Preclinical data suggest JAK inhibitors can impede the growth of common sporadic colon cancers.
• Targeting cytokine-dependent JAK/STAT3 activation offers therapeutic avenues for resistant cancers.

Conclusions:

• Therapeutic inhibition of the JAK/STAT3 pathway holds significant promise for treating various solid tumors.
• JAK inhibitors are effective in preclinical models and show potential for gastric and colon cancers.
• Interference with the JAK/STAT3 pathway presents a viable strategy for overcoming drug resistance in oncogene-driven cancers.